American Society of Hirudotherapy

Nail Psoriasis (Investigational Adjunct)

Investigational adjunct for nail psoriasis; topical corticosteroids, intralesional steroid, and (for severe disease) systemic biologics remain evidence-based.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for nail psoriasis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?
Tier C (investigational). No study of leech therapy has reported nail outcomes in psoriasis; the few small studies in skin psoriasis did not assess the nails. Evidence-based first-line management of nail psoriasis is topical corticosteroid (often with calcipotriene), intralesional triamcinolone for matrix or bed involvement (limited by pain), and for moderate-to-severe disease or when concurrent skin or joint psoriasis is present, systemic therapy — methotrexate, apremilast, or biologic agents (anti-TNF, anti-IL-17, anti-IL-23), all of which have FDA approval for psoriasis.
Main risks
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Bleeding around the nail unit that may dislodge already loose nails
  • Aeromonas or other bacterial infection of the nail bed and periungual tissue
  • Permanent nail dystrophy or matrix injury
Who should not consider this
  • Patients with concurrent skin or joint psoriasis (these need systemic therapy that will also treat nails)
  • Patients who have not tried topical therapy under dermatology guidance
  • Patients with active fungal nail infection (different management needed)
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with anemia
  • People with an active infection at the planned application site
What to ask your clinician
  • Has fungal nail infection been excluded by KOH preparation or culture?
  • Do I have skin or joint psoriasis that warrants systemic therapy that would also treat my nails?
  • Have I tried topical corticosteroid with or without calcipotriene?
  • What is the published evidence base for leeches in nail psoriasis?
  • What is the risk of permanent nail matrix injury from bites near the nail?
  • How will success be measured — NAPSI score, photographs, both?
When to seek urgent care
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Severe pain, swelling, or pus around a nail (possible paronychia or abscess)
  • Spreading redness up the finger or hand
  • New joint pain and swelling — possible psoriatic arthritis requiring systemic therapy

What this does NOT mean

  • It does not mean leech therapy is FDA-cleared for nail psoriasis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace topical, intralesional, or systemic therapy with FDA-approved psoriasis treatments.
  • It does not stop the underlying immunologic process driving psoriasis.
  • It does not address concurrent psoriatic arthritis, which needs systemic therapy.
  • It does not have RCT evidence for nail psoriasis; no study of leech therapy reporting nail outcomes was identified.

Clinical Profile

Category
Dermatological
ICD-10
L40.86, L40.0
Safety tier
High

Evidence Summary

Nail psoriasis affects up to half of patients with cutaneous psoriasis and a majority of those with psoriatic arthritis, presenting as pitting, onycholysis, subungual hyperkeratosis, and oil-drop discoloration. Evidence-based topical therapy includes high-potency corticosteroids, vitamin D analogs, and tazarotene applied to the proximal nail fold. Intralesional corticosteroid injection has supporting evidence for refractory disease. Severe nail psoriasis often warrants systemic therapy, especially biologics targeting IL-17 and IL-23, which produce superior nail outcomes versus methotrexate. No study of hirudotherapy reporting nail outcomes in psoriasis was identified in PubMed, Europe PMC, Crossref or Russian-language sources as of October 2026. Leech therapy for skin psoriasis has been tried in a few small studies, for example Senchukova 2012 (22 treated versus 20 control patients) and Iqbal 2018 (40 patients, single group, open), which scored skin with PASI and did not report the nails. The digital arteries and nail matrix make finger placement uniquely high-risk for ischemia and persistent bleeding.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan do not describe nail psoriasis; they name only psoriasis in general — in the list of conditions in which leech treatment is recommended and in the list of dermatological indications; nails are not mentioned in connection with psoriasis in the book, and the authors themselves note that there are few publications on hirudotherapy in such conditions (they refer to works from 1941 and 1983)[B1].
  • About the treatment of the diseases on this list as a whole they write (without saying whose observations these are): as early as day 4–5 the skin lesions paled, the infiltrate resolved and the general condition improved, and relapses were milder; the text does not attribute this to psoriasis, still less to the nails, and there are no numbers of patients[B1].
  • Michalsen et al. do not write about nail psoriasis or about leech treatment of psoriasis; but in the section on arthrosis of small joints, Flecken and Michalsen warn: leeches must not be applied to the joint regions of the fingers and toes that are not covered by a sufficient layer of subcutaneous tissue, because with thin skin and subcutaneous cover leeches generally do not have an adequate effect, and wound healing may be delayed and complications may occur; the book says nothing about the skin around the nails or the nail bed[B3].
  • Among the contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemias, low blood pressure and acute vascular insufficiency (shock, collapse, fainting), emaciation, concurrent use of anticoagulants (especially long-term and daily), concurrent use of alcohol, individual intolerance and an extremely negative attitude of the patient toward leeches, and at high body temperature they advise refraining from leeches[B1].
  • Flecken and Michalsen, in the chapter on contraindications, call hemophilia and the use of anticoagulants an absolute contraindication, and in anemia and bone-marrow suppression, according to them, any treatment involving blood removal is generally contraindicated; aspirin and clopidogrel are not contraindications in themselves, but at the first session they advise reducing the number of leeches and asking the patient about a tendency to bleed[B3].
  • In the appendix of Michalsen et al. (patient information and consent form), hirudotherapy is not performed, among other conditions, in blood diseases, acute gastric ulcer or erosive gastritis, immune deficiency (AIDS, chemotherapy), severe chronic diseases (advanced cancer, dialysis), a history of poor wound healing (for example, with poorly controlled diabetes, obesity and long-term cortisone treatment), known allergy to the active substances in leech saliva, and a tendency to keloids or scarring; the same document asks the patient not to use perfumed lotions, shower gels, medicinal ointments and oils on the day before and on the day of the procedure[B3].
  • Baskova and Isakhanyan consider hirudotherapy relatively contraindicated where leeches could potentially lead to cosmetic defects, and they call prescribing leeches in large numbers, for long periods, without breaks or with short breaks unjustified and impermissible[B1].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Placement on the digit, nail matrix, or eponychium (ischemia and persistent bleeding risk)
  • Raynaud phenomenon
  • Diabetes with peripheral vascular involvement
  • Active nail infection (paronychia, onychomycosis with bacterial superinfection)
  • Severe psoriasis where systemic therapy is indicated (refer to dermatology)

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.